Evidence map›Paper›PMID 21723893›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2011

Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates.

Jason Park, Thomas Mattessich, Steven M Jay, Atu Agawu, W Mark Saltzman, Tarek M Fahmy

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Development ofJournal of nanobiotechnology · 2024
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jason ParkYale University, Department of Biomedical Engineering, 55 Prospect Street, New Haven, CT 06511, USA.
Thomas Mattessich
Steven M Jay
Atu Agawu
W Mark Saltzman
Tarek M Fahmy
Yale University · USBrigham and Women's Hospital · US

Funding

Molecular and Cellular Transport in MucusR01EB000487 · NIBIB · YALE UNIVERSITY · PI IWASAKI, AKIKO, SALTZMAN, W. MARK · 2002 to 2019
$5.0M
Molecular and Cellular Transport in MucusR56EB000487 · NIBIB · YALE UNIVERSITY · PI SALTZMAN, W. MARK · 2008 to 2008
$402k
Engineering NRG Signaling For Therapeutic Vascularization In Diabetic WoundsK99HL112905 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI JAY, STEVEN MICHAEL · 2012 to 2013
$182k
NHLBI NIH HHS K99 HL112905NIBIB NIH HHS EB000487NIBIB NIH HHS R01 EB000487NIBIB NIH HHS R56 EB000487
6 · The paper itself

Abstract

Biodegradable polymeric nanoparticles are widely recognized as efficacious drug delivery vehicles, yet the rational engineering of nanoparticle surfaces in order to improve biodistribution, reduce clearance, and/or improve targeting remains a significant challenge. We have previously demonstrated that an amphiphilic conjugate of avidin and palmitic acid can be used to modify poly(lactic-co-glycolic acid) (PLGA) particle surfaces to display functional avidin groups, allowing for the facile attachment of biotinylated ligands for targeting or steric stabilization. Here, we hypothesized that the incorporation, density, and stability of surface-presented avidin could be modulated through varying the lipophilicity of its fatty acid conjugate partner. We tested this hypothesis by generating a set of novel conjugates incorporating avidin and common fatty acids. We found that conjugation to linoleic acid resulted in a ~60% increase in the incorporation of avidin on the nanoparticle surface compared to avidin-palmitic acid, which exhibited the highest avidin incorporation in previous studies. Further, the linoleic acid-avidin conjugate yielded nanoparticles with enhanced ability to bind biotinylated ligands compared to the previous method; nanoparticles modified with avidin-linoleic acid bound ~170% more biotin-HRP than those made with avidin-palmitic acid and ~1300% more than particles made without conjugated avidin. Most critically, increased ligand density on anti-CD4-targeted nanoparticles formulated with the linoleic acid-avidin conjugate resulted in a 5% increase in binding of CD4(+) T cells. Thus we conclude that the novel avidin-linoleic acid conjugate facilitates enhanced ligand density on PLGA nanoparticles, resulting in functional enhancement of cellular targeting.

Indexed as

AnimalsAvidinBiocompatible MaterialsCD4-Positive T-LymphocytesCells, CulturedDrug CarriersDrug StabilityFluorescein-5-isothiocyanateLactic AcidLigandsMiceMicroscopy, Electron, ScanningNanoparticlesPalmitic AcidParticle SizePolyglycolic AcidAvidinBiocompatible MaterialsDrug CarriersFluorescein-5-isothiocyanatefluorescein isothiocyanate bovine serum albuminLactic AcidLigandsPalmitic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSerum Albumin, BovineSurface-Active Agents

Identifiers

PMID21723893
PMCPMC3800156
OpenAlexW1998642701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.